Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.
Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.
Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.
Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.
CareDx, Inc. (CDNA) announces its significant participation in the 43rd annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in Denver, Colorado, showcasing over 55 presentations on advancements in heart and lung transplantation. The presentation highlights the clinical benefits of HeartCare and AlloSure Lung, focusing on their utility in post-transplant care. Experts, including Dr. Jeffrey Teuteberg from Stanford, advocate for moving away from biopsies to molecular surveillance for better outcomes. The event takes place from April 19-22, underscoring CareDx's commitment to enhancing clinical decision-making with its non-invasive solutions. CEO Reg Seeto emphasizes that the research will provide insights into patient care.
CareDx, a leader in precision medicine for transplant patients, has announced its sponsorship of the 12th Congress of the International Pediatric Transplant Association (IPTA) from March 25-28, 2023, in Austin, Texas. The company will host a symposium titled "Paradigm Shifts in Pediatric Surveillance Testing: AlloSure and AlloMap in Action" on March 26, featuring expert speakers from notable institutions. CEO Reg Seeto emphasized CareDx's commitment to pediatric transplant innovation, highlighting advancements in non-invasive monitoring with their products, AlloSure and AlloMap. This event aims to enhance awareness and usage of these monitoring solutions among pediatric transplant professionals.
CareDx, Inc. (Nasdaq: CDNA) announced the American Society of Transplant Surgeons (ASTS) supports its AlloSure Kidney and AlloMap Heart testing for organ transplant surveillance. The ASTS position statement endorses the use of donor-derived cell-free DNA (dd-cfDNA) to monitor kidney transplant recipients, particularly to rule out subclinical antibody-mediated rejection (ABMR). It also recommends dd-cfDNA for heart transplants and peripheral blood gene expression profiling as a non-invasive diagnostic tool for heart transplant recipients over 55 days post-transplant. CEO Reg Seeto praised ASTS for this leadership.
CareDx, Inc. (NASDAQ: CDNA) announced it will not participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference due to scheduling conflicts. The Company is focused on providing high-value healthcare solutions for transplant patients and their caregivers. CareDx specializes in precision medicine, offering testing services and digital healthcare solutions throughout the transplant journey. The Company looks forward to releasing its next corporate update soon, indicating ongoing engagement with investors and stakeholders.
CareDx, Inc. (NASDAQ: CDNA), known as The Transplant Company™, announced its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference. The presentation is scheduled for Monday, March 6, 2023, at 4:35 PM ET. Investors can access the webcast by visiting CareDx's investor relations page at investors.caredxinc.com. CareDx is a leader in precision medicine solutions, offering innovative testing services and digital healthcare solutions for transplant patients throughout their journey.
CareDx, Inc. (NASDAQ: CDNA) announced the release of a Billing Article regarding MolDX Molecular Testing for Solid Organ Allograft Rejection, effective March 31, 2023. CEO Reg Seeto clarified that MolDX will not modify the foundational LCD but issued this article for clarification. Key points include reimbursement coverage for testing services, standalone billing for AlloSure Heart, which can now be billed separately from AlloMap Heart, and a pathway for multimodality testing with additional data. CareDx plans to engage further with MolDX and update their HeartCare submission and procedures accordingly.
CareDx, Inc. (NASDAQ: CDNA) has announced its eighth consecutive sponsorship of the National Kidney Foundation's Annual Kidney Patient Summit, scheduled for March 1-2, 2023, on Capitol Hill. This event aims to raise awareness about kidney disease during National Kidney Month. CareDx aims to enhance patient care and promote early detection of chronic kidney disease. The company invests in transplant innovations, supporting various legislative policies, including the Living Donor Protection Act. CEO Reg Seeto emphasized their commitment to improving the patient journey from early interventions to post-transplant monitoring.
CareDx, Inc. (Nasdaq: CDNA) reported its financial results for Q4 and the full year 2022. The company achieved full-year revenue of $321.8 million, a 9% increase from 2021, with Q4 revenue hitting $82.4 million, up 4% year-over-year. Testing volumes for AlloMap and AlloSure grew by 19% to approximately 182,000 tests for 2022. However, the net loss increased to $76.6 million for the year, from $30.7 million in 2021. Cash and equivalents stand at $293 million. For 2023, CareDx anticipates revenue between $328 million and $338 million.
CareDx, Inc. (NASDAQ: CDNA) announced its participation in the American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting in Scottsdale, Arizona, from February 23-25. The company will showcase advancements in molecular diagnostics and artificial intelligence aimed at improving the health of transplant patients. A symposium titled 'Elevating Transplant Care by Combining Molecular Diagnostics and Artificial Intelligence' is scheduled for February 24, featuring a panel of leading experts in transplantation. CareDx emphasizes its commitment to innovation and enhancing long-term allograft health.
